Chardan Capital Has Pessimistic View of RCKT FY2025 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) – Analysts at Chardan Capital reduced their FY2025 earnings per share (EPS) estimates for shares of Rocket Pharmaceuticals in a research report issued to clients and investors on Monday, May 12th. Chardan Capital analyst Y. Livshits now anticipates that the biotechnology company will earn ($2.32) per share for the year, down from their prior forecast of ($1.25). Chardan Capital currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Rocket Pharmaceuticals’ current full-year earnings is ($2.83) per share. Chardan Capital also issued estimates for Rocket Pharmaceuticals’ FY2026 earnings at ($2.05) EPS.

A number of other equities research analysts have also recently issued reports on the company. JPMorgan Chase & Co. dropped their price objective on Rocket Pharmaceuticals from $45.00 to $44.00 and set an “overweight” rating on the stock in a research note on Friday, May 9th. Scotiabank dropped their price target on Rocket Pharmaceuticals from $52.00 to $51.00 and set a “sector outperform” rating on the stock in a research note on Monday. BMO Capital Markets initiated coverage on Rocket Pharmaceuticals in a research note on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $42.00 price target on shares of Rocket Pharmaceuticals in a research note on Wednesday, April 9th. Finally, The Goldman Sachs Group dropped their price target on Rocket Pharmaceuticals from $15.00 to $13.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.82.

Rocket Pharmaceuticals Trading Up 11.1%

Shares of Rocket Pharmaceuticals stock opened at $6.72 on Thursday. Rocket Pharmaceuticals has a 12-month low of $4.55 and a 12-month high of $26.98. The stock has a market cap of $717.60 million, a P/E ratio of -2.44 and a beta of 1.02. The company has a quick ratio of 6.05, a current ratio of 6.05 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $6.97 and its 200-day moving average is $10.40.

Rocket Pharmaceuticals (NASDAQ:RCKT) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.02. During the same period in the prior year, the firm posted ($0.66) EPS.

Insiders Place Their Bets

In other news, insider Kinnari Patel acquired 21,099 shares of the stock in a transaction on Wednesday, April 9th. The shares were purchased at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the transaction, the insider now directly owns 26,774 shares of the company’s stock, valued at approximately $125,837.80. This represents a 371.79% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Gaurav Shah acquired 20,000 shares of the stock in a transaction on Thursday, April 10th. The shares were purchased at an average price of $5.08 per share, for a total transaction of $101,600.00. Following the transaction, the chief executive officer now directly owns 792,680 shares in the company, valued at approximately $4,026,814.40. This trade represents a 2.59% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 28.50% of the company’s stock.

Institutional Trading of Rocket Pharmaceuticals

Several large investors have recently modified their holdings of RCKT. Wellington Management Group LLP grew its holdings in shares of Rocket Pharmaceuticals by 24.5% during the 4th quarter. Wellington Management Group LLP now owns 13,995,177 shares of the biotechnology company’s stock worth $175,919,000 after purchasing an additional 2,753,033 shares in the last quarter. Suvretta Capital Management LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at about $32,267,000. Janus Henderson Group PLC boosted its stake in Rocket Pharmaceuticals by 111.0% in the fourth quarter. Janus Henderson Group PLC now owns 4,004,039 shares of the biotechnology company’s stock valued at $50,343,000 after buying an additional 2,106,699 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Rocket Pharmaceuticals by 3,163.9% in the fourth quarter. Point72 Asset Management L.P. now owns 1,569,823 shares of the biotechnology company’s stock valued at $19,733,000 after buying an additional 1,521,727 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new stake in Rocket Pharmaceuticals in the fourth quarter valued at about $18,428,000. 98.39% of the stock is owned by institutional investors and hedge funds.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.